Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial-Reference-Cited by-同舟云学术

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Published:2024-08 Issue:8 Volume:24 Page:909-921
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Satti Iman,Marshall Julia L,Harris Stephanie A,Wittenberg Rachel,Tanner Rachel,Lopez Ramon Raquel,Wilkie Morven,Ramos Lopez Fernando,Riste Michael,Wright Daniel,Peralta Alvarez Marco Polo,Williams Nicola,Morrison Hazel,Stylianou Elena,Folegatti Pedro,Jenkin Daniel,Vermaak Samantha,Rask Linnea,Cabrera Puig Ingrid,Powell Doherty Rebecca,Lawrie Alison,Moss Paul,Hinks Timothy,Bettinson Henry,McShane Helen

Funder

Wellcome Trust

European Commission

Coordination of Higher Education Personnel Improvement

NIHR Clinical Research Network Thames Valley and South Midlands

NIHR Oxford Biomedical Research Centre

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Reference26 articles.

1. The BCG story: lessons from the past and implications for the future;Fine;Rev Infect Dis,1989

2. Human challenge trials in vaccine development;Sekhar;Semin Immunol,2020